Pharma Innovation at Korea

- Business Opportunities in Korea -

October 23, 2014

Dahee JEONG

Director of Bio-Medical Industry,
Investment Promotion Department

Invest Korea, KOTRA
Location: Traditional Korean Houses, Seoul
Source: KOREA TOURISM ORGANIZATION
Seokguram, UNESCO World Heritage
Source: KOREA TOURISM ORGANIZATION
Location: God’s Playground at Seorak Mountain
Source: KOREA TOURISM ORGANIZATION
Location: Ole Trail, Jeju Island
Source: KOREA TOURISM ORGANIZATION
Korea’s Tangible Strengths

- World-Class Human Resource
- Sophisticated Domestic Market
- Global Leading Industries
- Superior Logistics
- Industrial Zones
- High-Tech Clusters
- IT Power
- Profitability
Free Trade Agreements of Korea

61% of world GDP, 46.2% of world trade volume, 39.7% of world population

In Effect
- USA, EU, Chile, Singapore, EFTA, ASEAN, India, Peru, Turkey

Concluded
- Australia, Canada, Colombia

Under Way
- China, Indonesia, Vietnam, Korea-China-Japan
**Korea, the innovation center**

<table>
<thead>
<tr>
<th></th>
<th>Country</th>
<th>R&amp;D intensity</th>
<th>Mfging capability</th>
<th>High-tech density</th>
<th>Tertiary efficiency</th>
<th>Researcher concentration</th>
<th>Patent activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>S. Korea</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Sweden</td>
<td>4</td>
<td>22</td>
<td>5</td>
<td>13</td>
<td>8</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>USA</td>
<td>10</td>
<td>24</td>
<td>1</td>
<td>37</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>4</td>
<td>Japan</td>
<td>5</td>
<td>6</td>
<td>8</td>
<td>30</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>Germany</td>
<td>9</td>
<td>3</td>
<td>6</td>
<td>25</td>
<td>17</td>
<td>6</td>
</tr>
</tbody>
</table>

- **R&D intensity**: R&D expenditure as a percentage of GDP
- **Mfging capability**: Mfgring value-added as a percentage of GDP and as a share of world total mfging value-added
- **High-tech density**: Number of high-tech public companies as a percentage of all publicly listed companies
- **Tertiary efficiency**: Annual science and engineering graduates as a percentage of the labor force and as a percentage of total tertiary graduates
- **Researcher concentration**: Professionals engaged in R&D per 1 million people
- **Patent activity**: Resident patent filings per 1 million residents and per $1 million of R&D spent

*Source: Bloomberg, 2014*
Based at the campus of Ewha Univ., Solvay will have access to a strong national and international network with universities and research institutes.

Source: SOLVAY Website (June, 2014)
Overview of KOTRA

1. Overview of KOTRA
2. Pharma Industry in Korea
3. Innovative Business Trends
KOTRA Headquarters
National IPA : Invest Korea

Ministry of Trade, Industry & Energy

KOTRA
Korea Trade-Investment Promotion Agency

TRADE Promotion

INVESTMENT Promotion

Contribution to the sustainable growth of Korean economy
One-Stop Service for Foreign Investors

**Pre-Investment**
- Market research,
- Partner Search,
- Site Survey …

**Execution**
- Gov’s Incentive Consultations,
- Administrative support, …

**Aftercare**
- Grievance resolution,
- employees search

**Government agencies**

**Local governments**

**Project Managers**

Overseas Network
42/122 Business Centers

Governments
Project Managers
Supporting Process of GOV. Incentives

Investment Consultation

- Site Support
  - Negotiation / Determination of Location
    - Local government, Investor
  - Application for FIZ Designation
    - Local government

- Cash Grant
  - Acceptance Of Investment Plan
    - Local government, Investor
  - Preliminary Review and Evaluation
    - MOTIE, Evaluation Committee

- Tax Reduction
  - Application For Tax Reduction
    - Investor
  - Review & Evaluation
    - MOTIE, MSIP, MW, etc

- Official Announcement Of FIZ Designation
  - Local government

- Consideration and Decision of Foreign Investment Committee

- Contract for Cash Grants
  - MOTIE, Local Government

- Notification of the Decision
  - MOFSE
Opportunities in Emerging Market

Pharmaceutical Market Prognosis

Key
Estimated sales – 2015
Estimated growth – 2010-2015 (compound annual growth rate)

- North America Sales $357.4bn Growth 1.5%
- Europe (EU countries) Sales $237.4bn Growth 2.2%
- South East & East Asia Sales $147.1bn Growth 15.3%
- Japan Sales $120.6bn Growth 3.3%
- Latin America Sales $100.9bn Growth 12.2%
- CIS Sales $33.5bn Growth 12.2%
- Indian Subcontinent Sales $32.1bn Growth 15.3%
- Europe (Non EU countries) Sales $27.6bn Growth 5.3%
- Africa Sales $25.0bn Growth 7.9%
- Oceania Sales $16.7bn Growth 3.9%
- Middle East Sales $15.4bn Growth 7.4%

*Manufacturer prices at CER.

Opportunities in Emerging Market

Sustainable Growth in Korea

- Test-bed Market
- High-Tech, Mid-Labor Cost
- Large Market
- Low Labor Cost
- Sophisticated Market
- High Labor Cost

Korea

CHINA

JAPAN
Korea Pharmaceutical Market

US$16billion Market with CAGR 7% (`02-`12)
14th ~ 15th Global Ranking
20% Annual Increasing Rate of Export

Unit: USD Billion

Source: KFDA (2014.2)
# Korean Pharmaceutical Market

## Major Exporting Countries (’11)

<table>
<thead>
<tr>
<th>Rank</th>
<th>Country</th>
<th>API</th>
<th>Product</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Japan</td>
<td>233,637</td>
<td>140,935</td>
<td>374,572</td>
</tr>
<tr>
<td>2</td>
<td>Vietnam</td>
<td>17,427</td>
<td>144,472</td>
<td>161,899</td>
</tr>
<tr>
<td>3</td>
<td>China</td>
<td>70,628</td>
<td>66,296</td>
<td>136,924</td>
</tr>
<tr>
<td>4</td>
<td>Turkey</td>
<td>37,338</td>
<td>48,577</td>
<td>85,915</td>
</tr>
<tr>
<td>5</td>
<td>U.S.</td>
<td>66,960</td>
<td>18,581</td>
<td>85,541</td>
</tr>
<tr>
<td>6</td>
<td>India</td>
<td>59,348</td>
<td>25,856</td>
<td>85,204</td>
</tr>
<tr>
<td>7</td>
<td>Brazil</td>
<td>16,421</td>
<td>63,027</td>
<td>79,448</td>
</tr>
<tr>
<td>8</td>
<td>Pakistan</td>
<td>1,586</td>
<td>69,495</td>
<td>71,081</td>
</tr>
<tr>
<td>9</td>
<td>Germany</td>
<td>56,306</td>
<td>14,428</td>
<td>70,734</td>
</tr>
<tr>
<td>10</td>
<td>Italy</td>
<td>45,944</td>
<td>7,351</td>
<td>53,295</td>
</tr>
<tr>
<td></td>
<td>Rest of World</td>
<td>444,868</td>
<td>395,012</td>
<td>839,880</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>1,055,463</td>
<td>994,030</td>
<td>2,049,493</td>
</tr>
</tbody>
</table>

Unit : USD thousand

Source: KFDA (2014.2)
<table>
<thead>
<tr>
<th>Rank</th>
<th>Company</th>
<th>Total Sales</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Dong-A</td>
<td>846.8</td>
<td>907.3</td>
<td>930.9</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Yuhan Co.</td>
<td>649.3</td>
<td>667.6</td>
<td>762.7</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Green cross</td>
<td>791</td>
<td>698.9</td>
<td>715.5</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Dae-won</td>
<td>672.2</td>
<td>711.1</td>
<td>664</td>
<td>-6%</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Hanmi</td>
<td>595</td>
<td>512.5</td>
<td>543.7</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>GSK Korea</td>
<td>465</td>
<td>506.2</td>
<td>473.2</td>
<td>-6.5%</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Novartis Korea</td>
<td>435.8</td>
<td>478.8</td>
<td>463.5</td>
<td>-3.2%</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>CKD Pharm</td>
<td>419.6</td>
<td>442.2</td>
<td>461</td>
<td>4%</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Pfizer Korea</td>
<td>422.8</td>
<td>452.7</td>
<td>418.8</td>
<td>-7.5%</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Jeil Pharm</td>
<td>431.3</td>
<td>462.9</td>
<td>426.8</td>
<td>-8%</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>LG Life Science</td>
<td>334.3</td>
<td>372.5</td>
<td>397.6</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Choong-wae</td>
<td>443.3</td>
<td>431</td>
<td>397</td>
<td>-8%</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Kwang Dong</td>
<td>289.4</td>
<td>313.3</td>
<td>331.8</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Bayer Korea</td>
<td>342.8</td>
<td>355.5</td>
<td>330.9</td>
<td>-6.9%</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Il-dong</td>
<td>338</td>
<td>338.5</td>
<td>326</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Handok</td>
<td>321</td>
<td>333.2</td>
<td>314.6</td>
<td>-5%</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Boryung</td>
<td>301</td>
<td>308</td>
<td>312</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Sanofi Aventis Korea</td>
<td>428</td>
<td>344</td>
<td>283.6</td>
<td>17.5%</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Astrazeneca Korea</td>
<td>247.3</td>
<td>261.8</td>
<td>270.2</td>
<td>3.2%</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Roche Korea</td>
<td>252</td>
<td>218.9</td>
<td>262.9</td>
<td>20.1%</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Dongwha</td>
<td>215.3</td>
<td>234.6</td>
<td>223.3</td>
<td>-5%</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Janssen Korea</td>
<td>210.3</td>
<td>232</td>
<td>218.6</td>
<td>-5.8%</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Shin Poong</td>
<td>225.7</td>
<td>224.9</td>
<td>212</td>
<td>-6%</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Wyeth Korea</td>
<td>161.7</td>
<td>184.2</td>
<td>201.4</td>
<td>9.4%</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Berna Biotech</td>
<td>277.9</td>
<td>248</td>
<td>186.4</td>
<td>-24.8%</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Samjin</td>
<td>200.4</td>
<td>201.8</td>
<td>185.7</td>
<td>-7.96%</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Roche Diagnostics</td>
<td>143.7</td>
<td>170</td>
<td>183.4</td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Dong Kook</td>
<td>140.4</td>
<td>160.3</td>
<td>180.2</td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Boehringer ingerheim Korea</td>
<td>148.8</td>
<td>175.2</td>
<td>18.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Abbot Korea</td>
<td>174.4</td>
<td>169.2</td>
<td>-3%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Colored mark : Foreign invested MNC company

Source: Each company’s annual report / DART (2013 04)

Well-Established Local Players

- 60% Final drug’s production from Top 30, Top 5 Local players
Exporting High-Tech Production Facilities

Exporting construction know-hows to the developing countries

Blood Preparation Plant of Green Cross in Thailand

IV Solution MFG Plant of JW pharm in Kazakhstan
New Drug Development

As the 10th US FDA new drug development country in the world

*Source: Basic strategy for seven pharmaceutical nations of the world, Yakup News, 2013.8.16*
Potential for Korea Pharmaceutical Industry

By Product Type

- NCEs: 35% (217 Cases)
- Biologics (Biosimilars): 26% (161 Cases)
- Botanical Drugs: 8% (52 Cases)
- IMDs: 27% (166 Cases)
- Others: 4% (22 Cases)

By Stage

- Discovery stage: 64% (428 Cases)
- Phase 1: 17% (111 Cases)
- Phase 2: 9% (62 Cases)
- Phase 3: 10% (70 Cases)

Their 5yrs. Planning is to invest US $9billion into R&D

1. 43 Innovative Company Pipelines: 671
   - 68% - Incrementally Modified Drugs, Generics, or Biosimilars that can be Commercialized Soon

2. 124 to be Commercialized in the Global Market by 2014~2016
   - Possible Reinvestment Quantum Leap by Securing Jump-up Momentum

3. Considering the Success Possibility, 31 of New Drug Expected by 2020
   - Introduction of 20~30 Candidate Substances to Secure Global Blockbusters

Source: 2012 Innovative Pharmaceutical Companies R&D Pipeline Study, KHIDI
Biosimilar Development

Remsima™, the world first antibody biosimilar (approved in 2012 by KFDA)

- **Indications**: Rheumatoid Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Adult Crohn’s Disease, Psoriasis, Psoriatic Arthritis
- **Protein type**: Monoclonal antibody (mAb)
- **Mechanism of action**: Neutralizes tumor necrosis factor-α (TNF-α), a common cause of autoimmune diseases such as rheumatoid arthritis
- **Market size**: Approximately USD 24 billion (2011 TNF antagonist market)
Samsung in Bio-healthcare Business

- Biologics CMO plant in Incheon FEZ (‘11.5)

- Biz for R&D, sales and marketing of Biologics (‘12.1)

- M&A (‘11.2)
Korea: world’s best medical test-bed

Approval status of clinical trials in Korea

Seoul ranks world’s No.1
Superb Medical System

No. of in-patient beds per 1,000 inhabitants

Source: OECD Health Data 2013
As one of the fastest growing country in Asia in terms of clinical area, Korea has competitive factors thoroughly in high level open research labor, cost and quality, etc.

Joe Feczko, Senior Vice President, Chief Medical Officer
No.1
Stem cell technology
Stem Cell Technology

World-First Stem Cell Therapeutics to Get Market Approval

Hearticellgram-AMI  2011.7.

Cupistem  2012.1.

Medipost  2012.1.
Medical Healthcare Technology

Robotic System in Operating Room

Smart Hospital System of patient guide application and bedside station

Dr. Lee Sung-gyu
Liver Transplantation
Molecular / Genetic Technology

Disruptive Innovation using Lab-On-a-Chip Technology

- Downsizing
- Down Prices
- Movable
- Multifunction

Personalized Tool
Networking Tool
Point-Of-Care Tool
U-Healthcare Technology

by NanoEnTek and SK Telecom

Home
- Mobile Health Monitoring
- Vital signs measurement
- Location tracking

Chronic disease, Dementia old person, Chronic patients, Asylum for the aged

Hospital
- Local hospital (POL)
- Local hospital (Small and Medium)
- Clinical/Fitness Centers

POC device

Central hospital

Patient

Emergency out

On line

Korea Trade-Investment Promotion Agency
## Government Policy and Support

### Innovative Company Selection and Support (`13~)
- incentive expansion for companies to concentrate on R&D

### Development and Commercialization Support
- CRO nurturing, CMO activation, Partnerships, M&A

### Stem Cell Research / Brain Disease Research / Genome Projects
- Support for clinical trials, approval process, basic research

### Korean Drug Development Fund (KDDF)
- R&D matching fund (US$1,000M, `11-`20)

### National Onco Venture (NOV)
- R&D matching fund (US$240M, `11-`16)

### Promoting Bio clusters
- Daegu Medivally, Osong Biovalley
- Bio-Fund / Global Pharma Fund …
Korean Government investment in biotechnology
(Unit: $ billion)

- 2003: $530 billion
- 2004: $602 billion
- 2005: $674 billion
- 2006: $827 billion
- 2007: $879 billion
- 2008: $979 billion
- 2009: $1,262 billion
- 2010: $1,518 billion
- 2011: $1,592 billion
- 2012: $1,681 billion
International Joint R&D Development Initiatives

- **Global Advanced Technology Development Program**
  - Advance Technology Center: ATC track for foreign invested co.
  - Target: SMEs, FDIed R&D centers, research institutes and universities
  - Organization: KEIT

- **Int'l Cooperation Programs**
  - Bilateral Cooperation / Multilateral Cooperation
  - Target: Global market-oriented technology development of Korean enterprise
  - Organization: KIAT
International Joint R&D Development Initiatives

- **Global Advanced Technology Development Program**
  - Advance Technology Center: ATC track for foreign invested co.
  - Target: SMEs, FDId R&D centers, research institutes and universities
  - Organization: KEIT

- **Int’l Cooperation Programs**
  - Bilateral Cooperation / Multilateral Cooperation
  - Target: Global market-oriented technology development of Korean enterprise
  - Organization: KIAT
# Partnerships & Collaborations

## Research Institutes for Biotechnology

### Korea Research Institute of Bioscience and Biotechnology (KIRIBB)

Founded in 1985, KIRIBB conducts fundamental research on the origins of life phenomena as well as cutting-edge biotechnology research about new drug discovery, novel bio-materials, development of bio-energy sources, and expansion of food production.

**Mission**

To carry out R&D and related projects in the field of bioscience and biotechnology in joint effort with other research institutes, academic, and businesses at home and abroad.

To disseminate the results of its scientific research and technological development.

For more information, please visit the website - www.kirib.re.kr

### Korea Research Institute of Chemical Technology (KRICT)

Established in 1976, the KRICT has fueled the growth of Korea's chemical industry. The institute recently selected 4 key research areas for concentrated investment: the development of eco-friendly chemical process technology and high value-added green chemical materials, the acquisition of new substance pipelines for disease treatment, and the development of green convergence chemical technology to act as future growth engines.

**Mission**

KRICT seeks to improve the competitiveness of the chemical industry and promote the establishment of new national scale industries by developing and disseminating original chemical technologies and relevant convergence technologies; and by managing the public chemical technology infrastructure.

For more information, please visit the website - www.kRICT.re.kr

### International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is an international nonprofit organization that was founded on the belief that the health of children in developing countries can be dramatically improved by the use of new and improved vaccines.

IVI is hosted by the Republic of Korea and is headquartered in the country’s capital city, Seoul. The Institute’s state-of-the-art facility was built with the generous support of the Korean government and houses Biosafety Level 3+ (BSL3+) laboratories, which allow vaccine research on dangerous pathogens such as those that cause avian influenza and tuberculosis.

**Mission**

Discover, develop, and deliver safe, effective and affordable vaccines for the world’s developing nations.

For more information, please visit the website - www.ivi.int

### National Cancer Center (NCC)

Founded in 2000, the NCC has persevered to lessen the burden of cancer for Koreans by conducting and offering assistance to cancer research, diagnosing and treating cancer patients, assisting in the National Cancer Control Initiatives, and finally, educating and training cancer specialists.

**Mission**

The NCC strives to improve national health and welfare by reducing the incidence and mortality of cancer through research, patient care, education & training, and support for the national cancer control programs.

For more information, please visit the website - www.ncc.re.kr

### Korea Institute of Oriental Medicine (KIONM)

KIONM is the only government-funded research institute for traditional Korean medicine. Since its establishment in 1994, KIONM has strived to develop future-oriented original technology for Korean medical treatments, develop core technology of Korean medicine-based herbal drugs to support the National Agenda, and establish Korean medical knowledge and the informatics infrastructure based on medical knowledge accumulated over centuries. Through these efforts, the institute is taking the lead in scientific advancement, standardization, industrialization and globalization of Korean medicine.

**Mission**

The mission of KIONM is to creatively develop Korean medicine, building its new values and contributing to healthy life.

For more information, please visit the website - www.kiom.re.kr

### Korea Food Research Institute (KFRI)

Korea Food Research Institute, the cradle of Korea’s food science and technology, is a government-funded entity established in 1988 so as to contribute to the development of food, agriculture, forestry and fisheries industries and to the improvement in the quality life of the people by means of developing, diffusing and intensifying fundamental technologies in the field of food science.

**Mission**

Conducting researches on longevity science, functional foods, safe distribution and food processing technology to improve the health of the people and the quality of their life, spreading the research achievements; providing technological support.

For more information, please visit the website - www.kfri.re.kr
Overview of KOTRA

Biopharma Industry in Korea

Open Innovation Trends
**Venture Investment Cases**

**Global Alliance Projects (‘08, ‘10)**
- **KRW 20 Billion** investment plan only in Korea for next 5 yrs
- “**Novartis Venture Fund**” invested in 3 Korean Bio-ventures through GAPS
- **Working group with KOTRA and KHIDI, ...**

**Biz. Cases**

**NOVARTIS**

- **Neomics (2008)**
  - siRNA tech. for Novel cancer target; multiple modalities
  - CEO: Mr. Chiuk In
  - Founder: Prof. Sunghoon Kim, from Seoul National University

- **PharmAbcine (2009)**
  - Bi-specific Ab against VEGF-receptor target
  - Affiliation with KRIBB
  - CEO&Founder: Dr. Jin-San Yoo
  - Syndicated investment by OrbiMed (US), GrGeenCross investment(Kr)...(USD 6M)

- **Quroscience (2010)**
  - PhenoScreen Platform Tech., Anti-HIV, Anti-TB, Anti-HCV
  - Affiliation with Institute Pasteur Korea
  - GATE II winner
  - CEO: Dr. Ulf Nehrbrass
Dong-A Pharmaceutical Develops a Global Biopharmaceutical Industry Complex in Songdo (IFEZ), KOREA

Dong-A challenges global market through antibody based biosimilar production. Dong-A and Meiji Seika Pharma. Co., Ltd. (President: Masahiko Matsuo) signed agreement to comprehensive collaboration on development of biosimilar on September 14, 2011 in Tokyo, Japan. Dong-A and Meiji agreed to develop and commercialize three biosimilars including Herceptin, while the other pipelines are yet to be determined. A cGMP level plant is being designed to cope with the US, EU and Japan standard. Groundbreaking is expected in early next year and it is expected to be completed within following two years.

Battelle and YuYu Pharma Create the First “Joint Bioequivalence Test Experimentation Biz”…

Civic and business officials gathered in Chuncheon City Sept. 23, 2009 to open a worldwide bioequivalence research institute operated by International Scientific Standard, Inc. (ISS), a joint venture company. BE testing services begin in the fall in the GLP-compliant laboratory, which will begin operation with 10 to 20 researchers. They'll conduct the work in a 1,090-square meter facility in Chuncheon City that is equipped with state-of-the-art LC/MS equipment imported from Japan and the US.
• Phase 1 Clinical Trial is in progress
- Lung and gastric cancer new drug candidate substance

“Platform for incurable disease“

Sanofi and Bioneer work together in solid cancer using nanoparticle medicine (SAMiRNA) developed by Bioneer.

They will verify the effectiveness of target gene and start clinical trials about new drug candidates.

“Open Innovation“


Lego Chem Bio has new drug composite technologies (LegoChemistry) and the early pharmacometrics technologies.
Concluding Thoughts

● OPEN INNOVATION AND NETWORKING
  - Offer opportunities to work within alliance with complementary companies

● TAPPING INTO REGIONAL INNOVATIVE STRENGTHS
  - Source local capital, labor, knowledge and creativity

● WE BID TO WIN
  - Jointly develop and win projects aligned with policy initiatives
For our Growth Proposition

We Need “Open Innovation”

- Technology
- Human Resources
- Clinical Trials System
- Medical Application
- Policy Support
- Fundraising

[Map with flags of Turkey and South Korea]
THANK YOU.

Dahee Jeong

Director of Bio-medical Industry, Invest KOREA
daheej@kotra.or.kr